X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

T-Bird Pharma Inc. to be British Columbia’s first Health Canada Licensed Publicly Traded Medical Marijuana Company

Yuvraj_pawp by Yuvraj_pawp
9th September 2014
in Americas, News

T-Bird Pharma Inc., a pharmaceutical company focused on developing premium quality medical marijuana products, is pleased to announce that its shares will begin trading on the TSX Venture Exchange on September 9, 2014.  The Company’s wholly-owned subsidiary, Thunderbird Biomedical Inc. (“Thunderbird”), is licensed under the Marihuana for Medical Purposes Regulations (Canada) (“MMPR”) overseen by Health Canada.  T-Bird will be British Columbia’s first publicly traded medical marijuana company.  Thunderbird is one of 13 companies in Canada licensed under the MMPR.

On September 5, 2014, the Company announced the completion of its $3 million equity financing.  The agent on the financing was Richardson GMP Ltd. and the proceeds will enable the Company to bring online two additional grow rooms at their existing Victoria based facility and accelerate expansion to a second larger facility, also located on Vancouver Island, as the Company moves towards commercialization.  Additional updates on the new facility will be available in the coming weeks.

“After spending much of the past year assembling our team and developing our technology driven processes we are excited to be moving the Company forward towards providing a premium quality medical marijuana product to Canadian patients under the MMPR.  Our pharmaceutical grade approach aims to ensure repeatable, scalable and consistent medical marijuana products,” said Rob Gagnon, founder of Thunderbird and CEO of T-Bird.  “Over the next few months we will be working towards further expansion of not only our growing facilities, but also adding key scientific advisors to our team”.

The Company has an existing portfolio of over 60 high grade premium medicinal strains of marijuana, which it refers to internally as “varietals”, and which includes such well known strains as:  Island Honey, Pink Kush and Blue God.  Thunderbird’s focus is on working with BC developed strains.  BC has developed a reputation for expertise in this subject matter and strains that have become synonymous with quality.

“Our business model has been to start with a small facility to perfect our processes which have been architected to be scalable and repeatable.  We believe the market opportunity is only going to grow and we intend to be well positioned to increase capacity while ensuring quality of product” noted incoming Chairman, David Raffa.  Added Raffa, “With the initial financing now done and a strong financial partner in Richardson GMP, we are well positioned to do what is necessary to grow the business.”

Tags: America
Previous Post

Cold Chain Technologies Supports the Boston Marathon® Jimmy Fund Walk Insulated packaging leader is the official sponsor of Refueling Station #6 in Wellesley, Massachusetts

Next Post

Kinex completes acquisition of QuaDPharma

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Kinex completes acquisition of QuaDPharma

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In